Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population (Phase I)

Summary:

Gastrointestinal (GI) complications due to immune checkpoint inhibitor (ICPI) therapy can be a severe side-effect that can be life-threatening for cancer patients. In 30-50% of cases, the standard therapy to treat these GI complication does not work. This trial is testing the effectiveness and safety of a fecal microbiota transplant (FMT) to treat GI complications. If proven to be safe and effective, FMT will be a groundbreaking milestone for the management of ICPI-related GI complications in cancer patients.